Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues
Avascular tissues, such as articular cartilage, meniscus, intervertebral discs, and cornea stroma, pose a number of challenges for disease treatment. Systemic therapies will not reach the target tissue at efficacious levels. Local therapies are rapidly cleared from the tissue due to turnover of biol...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Published: |
Massachusetts Institute of Technology
2023
|
| Online Access: | https://hdl.handle.net/1721.1/151302 |
| _version_ | 1826215107478159360 |
|---|---|
| author | Johnston, Brandon Michael |
| author2 | Hammond, Paula T. |
| author_facet | Hammond, Paula T. Johnston, Brandon Michael |
| author_sort | Johnston, Brandon Michael |
| collection | MIT |
| description | Avascular tissues, such as articular cartilage, meniscus, intervertebral discs, and cornea stroma, pose a number of challenges for disease treatment. Systemic therapies will not reach the target tissue at efficacious levels. Local therapies are rapidly cleared from the tissue due to turnover of biological fluids, but repeated administration causes tissue damage and poor patient compliance. One method of improving the residence time of treatments is by utilizing drug delivery systems that target and bind to the extracellular matrix (ECM) with high affinity. The ECM is composed of a dense mesh of collagen and highly anionic proteoglycan chains. As such, small, cationic nanocarriers have been studied to electrostatically bind to avascular tissues and deliver therapeutics for extended periods.
Recently, cationic poly(amido amine) dendrimers partially modified with poly(ethylene glycol) chains (PEG-PAMAM conjugates) have shown promise in electrostatic based drug delivery to articular cartilage to treat osteoarthritis (OA), a debilitating disease of synovial joints affecting millions of people. Currently, there are no cures for OA. Though PEG-PAMAM conjugates have shown promise in delivering biologics to treat the disease, and have great potential for delivery to other avascular tissues, the impact of PEGylation on the surface charge presentation and drug delivery properties of these conjugates had not been well studied.
The first part of this thesis developed an experimental technique to probe how PEG chain length and chain density impact the charge presentation of PEG-PAMAM conjugates. This technique facilitated quantification of important characteristics like non-covalent interactions between PEG and PAMAM and the number of cationic amines on the dendrimer surface accessible to the physiological environment. A number of drug delivery properties to articular cartilage, such as binding kinetics, diffusion, biocompatibility, and pharmacokinetics, were probed using ex vivo, in vitro, and in vivo models, and a mechanistic understanding of how PEG influences these properties was achieved. Increasing accessible charged amines by reducing PEG chain density or chain length increased electrostatic binding strength while longer PEG chains improved binding reversibility. By controlling binding strength and reversibility, specific delivery profiles could be achieved and fine-tuned.
The second part of this thesis improved the bioconjugation of proteins to PEG-PAMAM conjugates and expanded the platform to other biologics and tissues. A robust scheme using click chemistry was introduced, improving loading efficiency while conserving protein bioactivity. Protein content influenced drug delivery properties to articular cartilage in a predictable manner, and improved joint residence times of proteins 20-fold. An anabolic protein and anti-catabolic protein, both with OA therapeutic potential, were loaded onto PEG-PAMAM conjugates and delivered to an in vivo OA model. Preliminary results show sustained delivery of the anti-catabolic protein relieved pain while both proteins showed signs of reduced OA severity compared to free proteins. Finally, the platform was explored in meniscus in the context of controlling intra-articular trafficking, where the partitioning of conjugates between cartilage and meniscus was dependent on the protein corona of the nanoparticle. These findings inform optimization of PEG-PAMAM conjugates for future drug delivery applications to avascular tissue, and provide preclinical development crucial for translation. |
| first_indexed | 2024-09-23T16:16:41Z |
| format | Thesis |
| id | mit-1721.1/151302 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T16:16:41Z |
| publishDate | 2023 |
| publisher | Massachusetts Institute of Technology |
| record_format | dspace |
| spelling | mit-1721.1/1513022023-08-01T03:05:10Z Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues Johnston, Brandon Michael Hammond, Paula T. Massachusetts Institute of Technology. Department of Chemical Engineering Avascular tissues, such as articular cartilage, meniscus, intervertebral discs, and cornea stroma, pose a number of challenges for disease treatment. Systemic therapies will not reach the target tissue at efficacious levels. Local therapies are rapidly cleared from the tissue due to turnover of biological fluids, but repeated administration causes tissue damage and poor patient compliance. One method of improving the residence time of treatments is by utilizing drug delivery systems that target and bind to the extracellular matrix (ECM) with high affinity. The ECM is composed of a dense mesh of collagen and highly anionic proteoglycan chains. As such, small, cationic nanocarriers have been studied to electrostatically bind to avascular tissues and deliver therapeutics for extended periods. Recently, cationic poly(amido amine) dendrimers partially modified with poly(ethylene glycol) chains (PEG-PAMAM conjugates) have shown promise in electrostatic based drug delivery to articular cartilage to treat osteoarthritis (OA), a debilitating disease of synovial joints affecting millions of people. Currently, there are no cures for OA. Though PEG-PAMAM conjugates have shown promise in delivering biologics to treat the disease, and have great potential for delivery to other avascular tissues, the impact of PEGylation on the surface charge presentation and drug delivery properties of these conjugates had not been well studied. The first part of this thesis developed an experimental technique to probe how PEG chain length and chain density impact the charge presentation of PEG-PAMAM conjugates. This technique facilitated quantification of important characteristics like non-covalent interactions between PEG and PAMAM and the number of cationic amines on the dendrimer surface accessible to the physiological environment. A number of drug delivery properties to articular cartilage, such as binding kinetics, diffusion, biocompatibility, and pharmacokinetics, were probed using ex vivo, in vitro, and in vivo models, and a mechanistic understanding of how PEG influences these properties was achieved. Increasing accessible charged amines by reducing PEG chain density or chain length increased electrostatic binding strength while longer PEG chains improved binding reversibility. By controlling binding strength and reversibility, specific delivery profiles could be achieved and fine-tuned. The second part of this thesis improved the bioconjugation of proteins to PEG-PAMAM conjugates and expanded the platform to other biologics and tissues. A robust scheme using click chemistry was introduced, improving loading efficiency while conserving protein bioactivity. Protein content influenced drug delivery properties to articular cartilage in a predictable manner, and improved joint residence times of proteins 20-fold. An anabolic protein and anti-catabolic protein, both with OA therapeutic potential, were loaded onto PEG-PAMAM conjugates and delivered to an in vivo OA model. Preliminary results show sustained delivery of the anti-catabolic protein relieved pain while both proteins showed signs of reduced OA severity compared to free proteins. Finally, the platform was explored in meniscus in the context of controlling intra-articular trafficking, where the partitioning of conjugates between cartilage and meniscus was dependent on the protein corona of the nanoparticle. These findings inform optimization of PEG-PAMAM conjugates for future drug delivery applications to avascular tissue, and provide preclinical development crucial for translation. Ph.D. 2023-07-31T19:29:50Z 2023-07-31T19:29:50Z 2023-06 2023-05-19T14:21:13.073Z Thesis https://hdl.handle.net/1721.1/151302 Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) Copyright retained by author(s) https://creativecommons.org/licenses/by-nc/4.0/ application/pdf Massachusetts Institute of Technology |
| spellingShingle | Johnston, Brandon Michael Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues |
| title | Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues |
| title_full | Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues |
| title_fullStr | Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues |
| title_full_unstemmed | Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues |
| title_short | Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues |
| title_sort | development of dendritic polymers as a modular drug delivery platform for avascular tissues |
| url | https://hdl.handle.net/1721.1/151302 |
| work_keys_str_mv | AT johnstonbrandonmichael developmentofdendriticpolymersasamodulardrugdeliveryplatformforavasculartissues |